Organon, the women’s health care company spun off from Merck, has completed its acquisition of Alydia Health, a medical device company focused on postpartum hemorrhage.
The Jersey City-based company’s deal is valued at up to $240 million, including $50 million upfront, $165 million upon close and $25 million in milestone payments.
“Organon’s acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’s unmet medical needs,” Kevin Ali, CEO of Organon, said in a prepared statement. “This acquisition brings us one step closer to our vision of a better and healthier everyday for every woman around the world.”
Organon formally spun off from Kenilworth-based Merck on June 3.
The deal was first announced in March.
